Secondary Analysis of Clinical Trials-A Cautionary Note

被引:13
|
作者
Marler, John R. [1 ]
机构
[1] US FDA, Div Neurol Prod, CDER, Silver Spring, MD 20993 USA
关键词
Secondary analysis; Clinical trial; Methodology; SUBGROUP ANALYSES;
D O I
10.1016/j.pcad.2011.09.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is concern in published reports and reviews that patients are being harmed or denied effective treatment by the use of questionable results from secondary analyses of data from clinical trials. A well-reported secondary analysis must make clear to the reader the uncertainty of the result -so clear, in fact, that it should be an obvious part of the conclusions that implementation should await confirmation as the primary outcome in an adequately powered trial. Those who write, review and publish these reports have a responsibility to ensure that reports accurately describe the sources of uncertainty, explain complex methods and their weaknesses with clarity, and convince readers to require better evidence before changing their practice. (Prog Cardiovasc Dis 2012;54:335-337) Published by Elsevier Inc.
引用
收藏
页码:335 / 337
页数:3
相关论文
共 50 条
  • [1] Clinical trials in nonulcer dyspepsia (NUD): A cautionary note
    Champion, MC
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY, 1997, 11 (02): : 125 - 126
  • [2] Principles for Defining Estimands in Clinical Trials-A Proposal
    Mutze, Tobias
    Bell, James
    Englert, Stefan
    Hougaard, Philip
    Jackson, Dan
    Lanius, Vivian
    Ravn, Henrik
    [J]. PHARMACEUTICAL STATISTICS, 2024,
  • [3] Hazard ratios in cancer clinical trials-a primer
    Blagoev, Krastan B.
    Wilkerson, Julia
    Fojo, Tito
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (03) : 178 - 183
  • [4] Noninferiority Margins in Clinical Trials-A Moving Target?
    Wang, Li
    Torguson, Rebecca
    Farb, Andrew
    [J]. JAMA CARDIOLOGY, 2022, 7 (03) : 327 - 329
  • [5] Cautionary note on regional consistency evaluation in multiregional clinical trials with binary outcomes
    Homma, Gosuke
    [J]. PHARMACEUTICAL STATISTICS, 2024, 23 (03) : 385 - 398
  • [6] Immunotherapies and immunomodulatory approaches in clinical trials-a mini review
    Iqbal Yatoo, Mohd.
    Hamid, Zeenat
    Rather, Izhar
    Nazir, Qurat Ul Ain
    Bhat, Riyaz Ahmed
    Ul Haq, Abrar
    Magray, Suhail Nabi
    Haq, Zulfqar
    Sah, Ranjit
    Tiwari, Ruchi
    Natesan, SenthilKumar
    Bilal, Muhammad
    Harapan, Harapan
    Dhama, Kuldeep
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (07) : 1897 - 1909
  • [7] Traditional plants with antioxidant properties in clinical trials-A systematic review
    Marmitt, Diorge Jonatas
    Bitencourt, Shanna
    da Silva, Gustavo Rodrigo
    Rempel, Claudete
    Goettert, Marcia Ines
    [J]. PHYTOTHERAPY RESEARCH, 2021, 35 (10) : 5647 - 5667
  • [8] PATH ANALYSIS - CAUTIONARY NOTE
    MAPES, REA
    ALLAN, GJB
    [J]. SOCIOLOGICAL REVIEW, 1973, 21 (01): : 137 - 144
  • [9] Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note
    Wang, Guoqiao
    Cutter, Gary R.
    Cofield, Stacey S.
    Lublin, Fred
    Wolinsky, Jerry S.
    Gustafson, Tarah
    Krieger, Stephen
    Salter, Amber
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (07) : 982 - 987
  • [10] Registry-based randomized clinical trials-a new clinical trial paradigm
    James, Stefan
    Rao, Sunil V.
    Granger, Christopher B.
    [J]. NATURE REVIEWS CARDIOLOGY, 2015, 12 (05) : 312 - 316